Cargando…

Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels

BACKGROUND: None of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs). METHODS: In this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon α-2b or monito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Qing-Lei, Yu, Zu-Jiang, Shang, Jia, Xu, Guang-Hua, Sun, Chang-Yu, Liu, Na, Li, Chun-Xia, Lv, Jun, Liu, Yan-Min, Liang, Hong-Xia, Li, Zhi-Qin, Pan, Ya-Jie, Hu, Qiu-Yue, Li, Wei, Zhang, Da-Wei, Wang, Fu-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324053/ https://www.ncbi.nlm.nih.gov/pubmed/32626791 http://dx.doi.org/10.1093/ofid/ofaa208

Ejemplares similares

Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
por: Chen, Lu, et al.
Publicado: (2020)

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B
por: Brakenhoff, Sylvia M, et al.
Publicado: (2022)

Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers
por: Li, Hong, et al.
Publicado: (2022)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen
por: Rico Montanari, Noe, et al.
Publicado: (2021)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients
por: Montanari, Noé R, et al.
Publicado: (2020)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
por: Howe, John A., et al.
Publicado: (2014)

The use of the circulating cathodic antigen (CCA) urine cassette assay for the diagnosis and assessment of cure of Schistosoma mansoni infections in an endemic area of the Amazon region
por: de Sousa, Sergei Rodrigo Magalhães, et al.
Publicado: (2020)

Hepatitis B Virus: Inactive carriers
por: Sharma, Sanjeev Kumar, et al.
Publicado: (2005)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design
por: Lau, Jillian S Y, et al.
Publicado: (2022)

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers
por: Huang, Yan, et al.
Publicado: (2021)

Inactıve hepatitis B surface antigen carriers and intrafamilial tramsmission: results of a 10-year study
por: Demirturk, Nese, et al.
Publicado: (2014)

Culture-Positive and Culture-Negative Empyema After Thoracoscopic Decortication: A Comparison of Short-term and Long-term Outcomes
por: Cheng, Ya-Fu, et al.
Publicado: (2023)

Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon
por: Wang, Xia, et al.
Publicado: (2018)

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis
por: Song, Aixin, et al.
Publicado: (2021)

Evaluation of a Cryptococcal Antigen Lateral Flow Assay and Cryptococcal Antigen Positivity at a Large Public Hospital in Atlanta, Georgia
por: Harrington, Kristin R V, et al.
Publicado: (2021)

Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study
por: Tang, Lin, et al.
Publicado: (2023)

Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection
por: Collins, Lauren F, et al.
Publicado: (2017)

Analysis of Genetic Diversity and Antibiotic Options for Clinical Listeria monocytogenes Infections in China
por: Yu, Wei, et al.
Publicado: (2021)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
por: Paltiel, A. David, et al.
Publicado: (2017)

Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven Model
por: Koren, David E, et al.
Publicado: (2019)

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
por: Li, Wen-cong, et al.
Publicado: (2011)

Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients
por: Kamimura, Hiroteru, et al.
Publicado: (2022)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole
por: Ruiz-Lancheros, Elizabeth, et al.
Publicado: (2018)

Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study
por: Pericot-Valverde, Irene, et al.
Publicado: (2023)

The Course of Mild and Moderate COVID-19 Infections—The Unexpected Long-Lasting Challenge
por: Xia, Lu, et al.
Publicado: (2020)

Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
por: Huo, Fengmin, et al.
Publicado: (2020)

Erratum to: Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
por: Chen, Lu, et al.
Publicado: (2021)

Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada
por: Marathe, Gayatri, et al.
Publicado: (2022)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
por: Hou, Feng-Qin, et al.
Publicado: (2015)

Correlation Between Prevalence of Selected Enteropathogens and Diarrhea in Children: A Case–Control Study in China
por: Huang, Zheng, et al.
Publicado: (2021)

Incidence and Predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study
por: Jain, Mamta K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_99b91cv1mm1d3fkc1ad2oenq03